-
Something wrong with this record ?
Histopathological assessment of the microscopic activity in inflammatory bowel diseases: What are we looking for
O. Fabian, L. Bajer
Language English Country United States
Document type Journal Article, Review
NLK
Free Medical Journals
from 1998
Freely Accessible Science Journals
from 1998
PubMed Central
from 1997
Europe PubMed Central
from 1997
- MeSH
- Crohn Disease * drug therapy MeSH
- Endoscopy adverse effects MeSH
- Inflammatory Bowel Diseases * complications MeSH
- Humans MeSH
- Intestinal Mucosa diagnostic imaging pathology MeSH
- Colitis, Ulcerative * pathology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
Advances in diagnostics of inflammatory bowel diseases (IBD) and improved treatment strategies allowed the establishment of new therapeutic endpoints. Currently, it is desirable not only to cease clinical symptoms, but mainly to achieve endoscopic remission, a macroscopic normalization of the bowel mucosa. However, up to one-third of IBD patients in remission exhibit persisting microscopic activity of the disease. The evidence suggests a better predictive value of histology for the development of clinical complications such as clinical relapse, surgical intervention, need for therapy escalation, or development of colorectal cancer. The proper assessment of microscopic inflammatory activity thus became an important part of the overall histopathological evaluation of colonic biopsies and many histopathological scoring indices have been established. Nonetheless, a majority of them have not been validated and no scoring index became a part of the routine bioptic practice. This review summarizes a predictive value of microscopic disease activity assessment for the subsequent clinical course of IBD, describes the most commonly used scoring indices for Crohn's disease and ulcerative colitis, and comments on current limitations and unresolved issues.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22033263
- 003
- CZ-PrNML
- 005
- 20230131151829.0
- 007
- ta
- 008
- 230120s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3748/wjg.v28.i36.5300 $2 doi
- 035 __
- $a (PubMed)36185628
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Fabian, Ondrej $u Clinical and Transplant Pathology Centre, Institute for Clinical and Experimental Medicine, Prague 14021, Czech Republic $u Department of Pathology and Molecular Medicine, 3rd Faculty of Medicine, Charles University and Thomayer Hospital, Prague 14059, Czech Republic. ondrej.fabian@ikem.cz
- 245 10
- $a Histopathological assessment of the microscopic activity in inflammatory bowel diseases: What are we looking for / $c O. Fabian, L. Bajer
- 520 9_
- $a Advances in diagnostics of inflammatory bowel diseases (IBD) and improved treatment strategies allowed the establishment of new therapeutic endpoints. Currently, it is desirable not only to cease clinical symptoms, but mainly to achieve endoscopic remission, a macroscopic normalization of the bowel mucosa. However, up to one-third of IBD patients in remission exhibit persisting microscopic activity of the disease. The evidence suggests a better predictive value of histology for the development of clinical complications such as clinical relapse, surgical intervention, need for therapy escalation, or development of colorectal cancer. The proper assessment of microscopic inflammatory activity thus became an important part of the overall histopathological evaluation of colonic biopsies and many histopathological scoring indices have been established. Nonetheless, a majority of them have not been validated and no scoring index became a part of the routine bioptic practice. This review summarizes a predictive value of microscopic disease activity assessment for the subsequent clinical course of IBD, describes the most commonly used scoring indices for Crohn's disease and ulcerative colitis, and comments on current limitations and unresolved issues.
- 650 12
- $a ulcerózní kolitida $x patologie $7 D003093
- 650 12
- $a Crohnova nemoc $x farmakoterapie $7 D003424
- 650 _2
- $a endoskopie $x škodlivé účinky $7 D004724
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a idiopatické střevní záněty $x komplikace $7 D015212
- 650 _2
- $a střevní sliznice $x diagnostické zobrazování $x patologie $7 D007413
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Bajer, Lukas $u Hepatogastroenterology Department, Institute for Clinical and Experimental Medicine, Prague 14021, Czech Republic $u Institute of Microbiology, Czech Academy of Sciences, Prague 14220, Czech Republic
- 773 0_
- $w MED00006918 $t World journal of gastroenterology $x 2219-2840 $g Roč. 28, č. 36 (2022), s. 5300-5312
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36185628 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151825 $b ABA008
- 999 __
- $a ok $b bmc $g 1891817 $s 1184598
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 28 $c 36 $d 5300-5312 $e 2022Sep28 $i 2219-2840 $m World journal of gastroenterology $n World J Gastroenterol $x MED00006918
- LZP __
- $a Pubmed-20230120